The 36-month beta value for GNLX is also noteworthy at -0.36. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for GNLX is 32.80M, and at present, short sellers hold a 6.36% of that float. The average trading volume of GNLX on July 09, 2025 was 149.83K shares.
GNLX) stock’s latest price update
The stock of Genelux Corp (NASDAQ: GNLX) has increased by 20.00% when compared to last closing price of $2.9.Despite this, the company has seen a gain of 21.25% in its stock price over the last five trading days. globenewswire.com reported 2025-07-07 that WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025.
GNLX’s Market Performance
Genelux Corp (GNLX) has experienced a 21.25% rise in stock performance for the past week, with a 37.55% rise in the past month, and a 45.61% rise in the past quarter. The volatility ratio for the week is 9.22%, and the volatility levels for the past 30 days are at 9.00% for GNLX. The simple moving average for the past 20 days is 19.36% for GNLX’s stock, with a 17.14% simple moving average for the past 200 days.
Analysts’ Opinion of GNLX
Many brokerage firms have already submitted their reports for GNLX stocks, with Guggenheim repeating the rating for GNLX by listing it as a “Buy.” The predicted price for GNLX in the upcoming period, according to Guggenheim is $8 based on the research report published on October 29, 2024 of the previous year 2024.
ROTH MKM, on the other hand, stated in their research note that they expect to see GNLX reach a price target of $10. The rating they have provided for GNLX stocks is “Buy” according to the report published on August 28th, 2024.
H.C. Wainwright gave a rating of “Buy” to GNLX, setting the target price at $35 in the report published on November 27th of the previous year.
GNLX Trading at 28.24% from the 50-Day Moving Average
After a stumble in the market that brought GNLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.87% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GNLX starting from Ryder Sean, who sale 4,475 shares at the price of $2.92 back on May 12 ’25. After this action, Ryder Sean now owns 47,621 shares of Genelux Corp, valued at $13,067 using the latest closing price.
Zindrick Thomas, the President and CEO of Genelux Corp, sale 10,764 shares at $2.92 during a trade that took place back on May 12 ’25, which means that Zindrick Thomas is holding 191,447 shares at $31,431 based on the most recent closing price.
Stock Fundamentals for GNLX
Current profitability levels for the company are sitting at:
- -69.46 for the present operating margin
- -0.45 for the gross margin
The net margin for Genelux Corp stands at -65.29. The total capital return value is set at -1.0. Equity return is now at value -131.36, with -92.71 for asset returns.
Based on Genelux Corp (GNLX), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -12.48.
Currently, EBITDA for the company is -28.97 million with net debt to EBITDA at 0.5. When we switch over and look at the enterprise to sales, we see a ratio of 258.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.67.
Conclusion
In summary, Genelux Corp (GNLX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
